Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. StemCell Institute's shares outstanding for the quarter that ended in Mar. 2026 was 10 Mil.
StemCell Institute's quarterly shares outstanding
stayed the same
from Sep. 2025 (10 Mil) to Mar. 2026 (10 Mil).
StemCell Institute's annual shares outstanding
declined
from Mar. 2025 (10 Mil) to Mar. 2026 (10 Mil).
It means StemCell Institutebought back shares from Mar. 2025 to Mar. 2026 .
StemCell Institute (TSE:7096) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
StemCell Institute Shares Outstanding (EOP) Related Terms
StemCell Institute Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, StemCell Institute's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Shares Outstanding (EOP) falls into.
StemCell Institute Shares Outstanding (EOP) Calculation
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 10 Mil mean?
StemCell Institute (TSE:7096) has a Shares Outstanding (EOP) of 10 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on StemCell Institute and its competitors.
Is StemCell Institute's Shares Outstanding (EOP) too high?
StemCell Institute's current Shares Outstanding (EOP) is 10 Mil. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Shares Outstanding (EOP) compare to VRTX and REGN?
StemCell Institute's Shares Outstanding (EOP) of 10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on StemCell Institute and its competitors. StemCell Institute's current Shares Outstanding (EOP) is 10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.82, compared to a current price of 円768.00 — trading 57.7% below its estimated fair value. The current Shares Outstanding (EOP) is 10 Mil. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Shares Outstanding (EOP) is 10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.7% below its estimated GF Value™ of 円1,813.82.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Shares Outstanding (EOP): 10 Mil
GF Value™: 円1,813.82 vs. price of 円768.00 (57.7% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
